Circulating Tumor Cells (CTCs) are present in the blood of all types of cancer patients, and originate from primary tumors and
metastasis. Migration and cell adhesion of these cells determine the future site of cancerous growth in the distant organ. The presence of CTCs in the blood could be used to develop suitable biomarkers to detect cancers that are difficult to diagnose, such as pancreatic, lung, brain and ovarian cancer. Isolating single CTCs from blood combined with molecular profiling using Nextgen sequencing could identify genes, miRNA or noncoding RNA to diagnose any cancer and provide significant clues for its treatment. To eradicate cancer, it is essential to kill all CTCs in the blood of cancer patients. Chemotherapy is the only way to treat them, since tumor surgery and radiation therapy are unable to completely remove them. However, very limited information is available about their biology, molecular mechanisms of spreading, cell adhesion and their overall responsiveness to different types of chemotherapy.The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Last date updated on January, 2021